Diarrhea – Cannabis Research

Diarrhea Research Dashboard

11

Primary Studies

41

Related Studies

52

Total Studies

Clinical Studies

0

Clinical Meta-analyses

1

Double-blind Clinical Trials

0

Clinical Trials

Pre-Clinical Studies

6

Meta-analyses/Reviews

3

Animal Studies

1

Laboratory Studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 52 studies associated with Diarrhea.

Here is a small sampling of Diarrhea studies by title:


Components of the Diarrhea Research Dashboard

  • Dosing information available for Diarrhea
  • Chemotype guidance for treating Diarrhea with cannabis
  • Synopsis of cannabis research for Diarrhea
  • Individual study details for Diarrhea

Ready to become a subscriber? Go to our PRICING page.

Diarrhea Research Dashboard

11

Primary Studies

41

Related Studies

52

Total Studies

Clinical Studies

0

Clinical Meta-analyses

1

Double-blind Clinical Trials

0

Clinical Trials

Pre-Clinical Studies

6

Meta-analyses/Reviews

3

Animal Studies

1

Laboratory Studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 52 studies associated with Diarrhea.

Here is a small sampling of Diarrhea studies by title:


Components of the Diarrhea Research Dashboard

  • Dosing information available for Diarrhea
  • Chemotype guidance for treating Diarrhea with cannabis
  • Synopsis of cannabis research for Diarrhea
  • Individual study details for Diarrhea

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Filter Condition

Overview - Diarrhea

Description of Diarrhea

Diarrhea is defined as the frequent passage of loose or watery stools, often accompanied by urgency, cramping, or abdominal discomfort. It occurs when the intestines move contents too quickly or fail to absorb enough fluids and nutrients, leading to increased water content in the stool. Diarrhea is broadly categorized as either acute or chronic, each with different causes, implications, and treatment approaches.


Acute Diarrhea (Lasting Less Than 14 Days)



  • Most often caused by infections—including viruses (e.g., norovirus, rotavirus), bacteria (e.g., E. coli, Salmonella), parasites, or fungi.

  • May follow the ingestion of contaminated food or water, or result from recent travel (traveler’s diarrhea).

  • Can also be triggered by certain medications (e.g., antibiotics, NSAIDs, chemotherapy agents) or supplements (e.g., high-dose vitamin C, magnesium, herbal laxatives).

  • Self-limited in most cases, resolving once the underlying cause is eliminated.

  • In some cases, particularly in young children, older adults, or those with compromised immunity—dehydration and electrolyte imbalance can become serious complications.


Chronic Diarrhea (Lasting More Than 14 Days)


Chronic diarrhea suggests underlying dysfunction in the gastrointestinal system and typically requires further evaluation. Common causes include:



  • Inflammatory conditions (Inflammatory Bowel Disease or IBD), such as Crohn’s disease or ulcerative colitis, involve immune system dysregulation.

  • Functional disorders like irritable bowel syndrome with diarrhea (IBS-D), often associated with altered gut-brain signaling and hypersensitive motility.

  • Microbiome imbalance (dysbiosis) often follows antibiotic overuse, poor diet, or infections.

  • Leaky gut syndrome or increased intestinal permeability can lead to immune activation and inflammation.

  • Endocrine conditions, such as hyperthyroidism, Addison’s disease, or diabetes-related enteropathy.

  • Malabsorption syndromes, including celiac disease, lactose intolerance, or bile acid diarrhea.

  • Chronic infections (e.g., Giardia lamblia, Clostridium difficile).

  • Toxins, including heavy metals or ongoing exposure to food additives.

  • Stress-related or psychological factors can significantly influence gut function through the gut-brain axis.

  • Post-surgical, including short-gut syndrome, or traumatic injury to the bowel, may disrupt normal digestive function.


For patients, understanding whether diarrhea is acute or chronic helps guide appropriate self-care vs. seeking medical attention. Persistent symptoms, signs of dehydration, or weight loss should always be evaluated by a clinician.


For clinicians, evaluating duration, frequency, stool characteristics, travel history, diet, medication use, and associated symptoms (e.g., blood in stool, fever, fatigue) can guide diagnosis and management. Stool studies, bloodwork, imaging, and colonoscopy may be necessary in chronic or unexplained cases.


 

Disease Classification

Condition: Diarrhea
Disease Family: Gastrointestinal Disorder
Organ System: Digestive System
ICD-10 Chapter: Symptoms, Signs and Abnormal Clinical and Laboratory Findings
ICD-10 Code: R19.7

Diarrhea Symptoms:

Diarrhea is considered mild when stools are slushy or mucinous in consistency, whereas completely liquid stools are typically classified as severe. The longer diarrhea persists—particularly in its severe form—the greater the risk of developing additional complications. These may include: abdominal pain or cramping, nutrient malabsorption, dehydration, electrolyte imbalances, low blood pressure, pale skin, generalized weakness, fever, weight loss, blood in the stool (hematochezia), kidney dysfunction, and in extreme cases, hypovolemic shock.

Also known as:

Loose stool, Watery stool, Frequent bowel movements, Increased hypermotility, Intestinal hypermotility, Gastroenteritis (often used when infection is involved), Enteric illness, Bowel urgency, Dysentery, the Runs, the Trots, Montezuma's revenge, Explosive diarrhea, Tummy trouble

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol. 
  • THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
  • Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.

CBD Interaction with Pharmaceutical Drugs

  • Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
  • Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.

If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.

THC/CBD Interaction with Pharmaceutical Drugs

In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.

If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.

Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).

However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg
  • THC low dose:  0.5 mg to 5 mg
  • THC medium dose:  6 mg to 20 mg
  • THC high dose:  21 mg to 50+ mg

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg
  • CBD medium dose: 20 mg to 99 mg
  • CBD high dose:  100 mg to 800+ mg (upper limits tested ~1,500mg)
Top

Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.